



London
STOCK EXCHANGE

techMARK mediscience® Where innovative healthcare companies make their MARK

techMARK mediscience is the specially developed international segment of London Stock Exchange's respected Main Market, designed for companies at the forefront of innovative mediscience development. It is a subset of the successful techMARK family of companies, designed to focus attention on companies who invest heavily in product research and development.

techMARK mediscience was launched in 2001 by the Exchange, to create new and exciting opportunities for companies whose business is dependent on innovation in the development or manufacture of drugs, or to produce products or services that are wholly or substantially dedicated to the healthcare industry. It is the only market segment in the world that is solely designed to meet the needs of these companies and their investors.

techMARK mediscience brings together companies whose business models require a particularly high level of innovation and investment into research and development programmes. By providing a spotlight on this segment of the Main Market, it allows techMARK mediscience companies to build successful relationships with investors – vital to innovation and funding discovery.

techMARK mediscience hits the spot

Together the Main Market and techMARK mediscience allow the innovative stars of tomorrow to visibly compete amongst their peers on the global stage.

Enjoy the prestige of being listed on London's Main Market:

- Gain access to one of the deepest and most liquid pools of capital in the world
- Be at the heart of global finance
- Demonstrate a commitment to world respected regulatory and corporate governance standards
- Increase your visibility amongst a wide and global investment community consisting of highly experienced and specialist advisers, analysts and investors.

And for scientific-research based companies, the Listing Rules take into account your business specialisation and facilitate your admission to the Main Market.

Be in the spotlight on techMARK mediscience:

- Gain clear identification and easier benchmarking against a comparable peer group
- Increase your awareness amongst investors – positively impacting profile and liquidity
- Benefit from inclusion in dedicated techMARK indices and associated funds
- Boost your profile even further with the additional coverage by media focused on these sectors.

Investors benefit by being able to better identify innovative healthcare companies and track their performance against clear benchmarking.

Who can join techMARK mediscience?

techMARK mediscience companies operate within the techMARK family, which is open to all innovative companies, regardless of size, sector of commercial or industrial activity, country of origin or currency of share trading. techMARK mediscience specifically includes healthcare sectors such as medical equipment, medical supplies, biotechnology and pharmaceuticals. However, they all share one key attribute – **innovation in healthcare research & development.**

To see if you are able to join techMARK and techMARK mediscience as well as to understand the admittance procedure please refer to our 'Eligibility Guidance' factsheet.

techMARK and techMARK mediscience Fast Facts

- 151 techMARK companies on market
- 36 techMARK mediscience companies
- 13 International companies
- Total capital raised £26 billion
- Total market value £306 billion
- Companies from 15 market sectors and 22 subsectors
- Traded value over £2,855 billion since launch.

Source: London Stock Exchange figures to July 2005



techMARK Indices – increasing investability and liquidity

The indices enable each company's performance to be measured against their peer group on the London market and allow techMARK companies as a group to be benchmarked against comparable companies on other markets. Grouping companies together in this way helps increase visibility and liquidity, whilst also raising the profile of techMARK companies with investors.

techMARK has three associated indices

- FTSE techMARK All-Share index includes all companies admitted to techMARK
- FTSE techMARK 100 index focuses on medium and smaller techMARK companies
- FTSE techMARK mediscience index features emerging healthcare companies.

The family of techMARK indices allows techMARK-eligible companies access to an index specifically tailored to reflect the nature of their business in addition to the normal UK FTSE range of indices. Your company therefore increases its exposure to indices on which funds base their investment decisions.



Ardana: development of innovative pharmaceutical products

Ardana was the first UK pharmaceutical company to list in 2005, and subsequently to join techMARK mediscience. The company focuses on the discovery, development and marketing of innovative products to improve human reproductive health.

The additional profile and focus that the techMARK mediscience segment of the Main Market attracts will provide Ardana with specific exposure in supporting their development into a global pharmaceutical player.

“Our admission to the LSE has given us access to the public markets and will allow us to further develop and commercialise our products. In addition, it will allow us to develop our sales and marketing capabilities in the top five European countries...”

Maureen Lindsay, Ardana's CEO

Date of Admission: 9 March 2005

Inion OY: biodegradable implants developer

On 1 December 2004, Inion became the first Finnish company to undertake a primary listing on the Main Market of the London Stock Exchange. The company operates in the medical devices sector, and develops and sells novel biodegradable implants, such as plates, screws and pins.

One of the key reasons for Inion coming to the Main Market was the extra profile that it would gain through membership of techMARK mediscience, with its associated investable index.

“We are delighted that our IPO has been such a success and are very proud to be the first Finnish company to IPO on London's Main Market.”

Auvo Kaikkonen, Inion's CEO

Date of Admission: 1 December 2004

For more information about techMARK, please contact:
Andrew Wallace
techMARK Product Manager
Tel: +44 (0)20 7797 1696
Email: awallace@londonstockexchange.com

London Stock Exchange plc
London EC4M 7LS
Telephone +44 (0)20 7797 1000

www.londonstockexchange.com

techMARK
mediscience

London Stock Exchange plc has used reasonable efforts to ensure that the information contained in this publication is correct at the time of going to press, but shall not be liable for decisions made in reliance on it. techMARK and techMARK mediscience are registered trade marks of the London Stock Exchange plc. The London Stock Exchange coat of arms and logo are trade marks of the London Stock Exchange plc. PRI/TEC/COL/017